Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.
about
Population pharmacokinetics of bevacizumab in cancer patients with external validationPharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers.Covariate pharmacokinetic model building in oncology and its potential clinical relevance.Failure of miltefosine in visceral leishmaniasis is associated with low drug exposurePharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaIntegrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokineticsCombined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in CatsPopulation Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive suPlatelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal OxaliplatinPerformance in population models for count data, part II: a new SAEM algorithmAge, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children.Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamicsPopulation pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIVModeling sleep data for a new drug in development using markov mixed-effects models.Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.OCT1 genetic variants influence the pharmacokinetics of morphine in children.Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjectsPopulation pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladderInfluence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphomaPopulation pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tabletsAxitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children.Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.Evaluation of effect of impaired renal function on lamivudine pharmacokineticsImproved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modellingPopulation pharmacokinetic meta-analysis of vortioxetine in healthy individualsImpact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis.Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy.Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
P2860
Q26779580-07296D0B-81EF-4A04-A256-A9F5233BF290Q27335488-8B4DB3B8-9CE1-4698-AD41-223A70E64735Q27687599-DDCCC290-34ED-4B96-B102-B7A18116964CQ28306178-272F25D8-9A64-46FB-BDEB-972EDCC19460Q28550488-887E4F12-FA21-4EEB-A642-FA10258AAEA8Q28650281-1B7645B4-610F-43E7-A66B-48F67C557E60Q31074808-301D68AE-1164-4D08-91B1-B4AEE7AE690AQ31138427-C688EA06-7D2D-43EE-AF5B-F438FE1121E7Q31153944-B9CBB9AF-01B1-45EC-8977-6DBFD092BB53Q33394332-D15C7322-923F-4143-9858-775A5E68EB81Q33416659-BB54FB2A-5A55-4CC9-AF82-A8DCDAF212D4Q33427607-B85A0FF6-0CA6-4BA3-8104-5F29F1EE403FQ33493457-45D97EAD-B2E2-4859-8BAA-E0A35CBA2D95Q33601837-88140C82-0593-46BD-B880-F834F5859E96Q33633622-24C306DE-D871-48F4-B424-1A0940D10C85Q33743151-EB40D4C3-A699-4371-B176-DD9E97F72FECQ33795052-F291875E-F6F8-4A9E-B4EA-802205EE6A5AQ33797999-571D3536-4F27-4D1A-B5D2-3F1D8682B0E4Q33935102-FD249A88-CB5B-44A6-BBBE-FE6F51699508Q33954595-0890C3B1-162E-41F3-AA74-253D895D1944Q33977906-B64F3464-170E-4EA1-9DFA-4E4D447A3B91Q33998845-CC3B3871-A97E-4EC5-BDB7-68215673D95BQ34019358-DCF83E4D-3D1F-468D-8A54-B0FA1C038469Q34174899-9EC4AC4D-284E-4937-B7C0-A5C1A7BDBA29Q34209542-BB884DAA-4F75-48B7-88C1-FA9FC603D8E1Q34245458-A7406B49-163C-46DB-B7E0-070DE1E06FA2Q34299178-F4DFA1DA-0075-40AB-BA16-563917DD52B1Q34308014-00BD14B3-AAB2-47A2-BECF-F1941AF62EEBQ34331026-DA316CA7-739F-498E-A956-4F67E2E35BCBQ34554449-7C160790-05EB-4239-ACAE-33B3C5CE4F16Q34571036-7E2CA9FD-758B-4219-A2AA-F7DC6F26CE9BQ34639656-452D2731-5F77-41A6-9E55-A44AB8F22586Q34710705-1EF71BC6-01ED-4182-8235-BF7A12641948Q34860261-B4E3E731-75D6-4245-AFCE-A9526BC6E622Q35105858-D2370C25-1BA5-410B-90F4-E9256E0B25EEQ35120597-375344C3-F527-4F25-B219-C5FDBB4B61FFQ35138216-EE60B381-21C7-415E-B3E5-AD6F4C2D68A8Q35164864-088BE050-70BB-408B-9D52-4D06D0680896Q35176909-EB5F38E2-BECF-429D-B473-E0F8ABAFED37Q35183640-FFEDE601-6555-457F-9A43-8DFF4E85ABD1
P2860
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Importance of shrinkage in emp ...... stics: problems and solutions.
@en
Importance of shrinkage in emp ...... stics: problems and solutions.
@nl
type
label
Importance of shrinkage in emp ...... stics: problems and solutions.
@en
Importance of shrinkage in emp ...... stics: problems and solutions.
@nl
prefLabel
Importance of shrinkage in emp ...... stics: problems and solutions.
@en
Importance of shrinkage in emp ...... stics: problems and solutions.
@nl
P2860
P1433
P1476
Importance of shrinkage in emp ...... stics: problems and solutions.
@en
P2093
Mats O Karlsson
Radojka M Savic
P2860
P2888
P304
P356
10.1208/S12248-009-9133-0
P407
P577
2009-08-01T00:00:00Z
P5875
P6179
1046129728